Vyndaqel 20 mg
As listed in the register: Vyndaqel 20 mg, Weichkapseln
20 mg ·
- Prescription only
- Pain, sleep, mood, epilepsy and the brain
- Active substance
- Tafamidisum
- Made by
- Pfizer AG
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Behandlung der Transthyretin-Amyloidose bei erwachsenen Patienten mit Wildtyp- oder hereditärer Kardiomyopathie
From the official label · 2026-09-30 · Swissmedic
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Pfizer AG |
|---|---|
| Active substance | Tafamidisum |
| Used in | Pain, sleep, mood, epilepsy and the brain |
| Strength | 20 mg |
| Classification | N07XX08 · Pain, sleep, mood, epilepsy and the brain |
| Dispensing (as stated by the register) | Abgabekategorie B |
| Name in the register | Vyndaqel 20 mg, Weichkapseln |
| Packs | 30 Kapsel(n) |
| Zulassungsnummer | 67083 |
| Dosisstärke | 1 |
Source: Zugelassene Packungen Humanarzneimittel · 2026-09-30 · not reviewed by a clinician
Quelle: Swissmedic. The publisher’s terms do not grant reproduction, so text is shortened and linked. Publisher’s terms.
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.